2. Padian NS, Buvé A, Balkus J, et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372:585–599. doi:10.1016/S0140-6736(08)60885-5. [PubMed] 3. Johnston M, Fauci AS. An HIV vaccine--evolving concepts. N Engl J Med. 2007;356:2073–2081. [PubMed] 4. Coates T, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet. 2008;372(9639):669–684. [PMC free article] [PubMed] 5. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. Clin Infect Dis. 2010;50 suppl 3:S85–S95. [PubMed] 6. Granich R, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48–57. [PubMed] 7. Granich R, Crowley S, Vitoria M, et al. Highly active antiretroviral treatment for the prevention of HIV transmission. J Int AIDS Soc. 2010;13:1. PMCID: PMC2822750. [PMC free article] [PubMed]
8. Mayer K. Antiretrovirals for HIV prevention: panacea or Pandora’s box? [paper #63]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; Francisco, CA.
9. Mayer K, Venkatesh KK. Antiretroviral therapy for HIV prevention: current status and future prospects. Am J Public Health. In press.
10. Cohen M, Kashuba AD. Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Medicine. 2006;5:e30. doi:10.1371/journal.pmed.0050030. [PMC free article] [PubMed]
11. American Thoracic Society, Centers for Disease Control, and Infectious Diseases Society of America. Treatment of tuberculosis [erratum in: MMWR Recomm Rep. 2005;53:1203] MMWR Recomm Rep. 2003;52(RR11):1–77.
12. Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control. Sexually transmitted diseases treatment guidelines, 2006 [erratum: MMWR Recomm Rep. 2006;55:997] MMWR Recomm Rep. 2006;55(RR11):1–94.
13. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Recomm Rep. 2001;50(RR11):1–52. [PubMed] 14. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591–601. [PubMed] 15. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173–1180. [PubMed] 16. De Cock K, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175–1182. [PubMed] 17. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med. 1997;337:1485–1490. [PubMed] 18. Tsai C, Emau P, Follis KE, Beck TW, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72:4265–4273. [PMC free article] [PubMed] 19. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2005 54(RR21):1–20. [Accessed September 1, 2008]; Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5402a1.htm. [PubMed]
20. Diaz-Brito V, León A, Knobel H, et al. the DATEMPEP Study Group. An open randomized multicenter clinical trial comparing zidovudine/lamivudine (ZDV/3TC) plus lopinavir/ritonavir (LP/r) or plus atazanavir (ATV) used as postexposure prophylaxis (PEP) for HIV infection [paper #956]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; San Francisco, CA.
21. Mayer KH, Mimiaga MJ, Cohen D, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47:494–499. [PubMed]
22. Mayer K, Mimiaga M, Gelman M, et al. Tenofovir DF/emtricitabine/raltegravir (TDF/FTD/RAL) appears safe and well-tolerated for non-occupational post-exposure prophylaxis (NPEP) [abstract WEAC104]. Presented at: 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 19–22, 2009; Cape Town, South Africa.
23. Dumond J. Maraviroc (MRV) genital tract (GT) fluid and tissue pharmacokinetics (PK) in healthy female volunteers: implications for pre- or post-exposure prophylaxis (PrEP or PEP) [paper #135LB]. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3–6, 2008; Boston, MA.
24. Bassett I, Freedberg KA, Walensky RP. Two drugs or three? Balancing efficacy, toxicity, and resistance in postexposure prophylaxis for occupational exposure to HIV. Clin Infect Dis. 2004;39:395–401. [PubMed] 25. Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35:519–525. [PubMed] 26. Roland ME, Neilands TB, Krone MR, et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis. 2005;41:1507–1513. [PubMed]
27. Adamson P, Marcus J, Pipkin S, et al. Characteristics of and HIV seroconversion among patients receiving non-occupational HIV post-exposure prophylaxis in a sexually transmitted disease clinic: San Francisco, 2007 to 2009 [paper #958]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; San Francisco, CA.
28. Vourvahis M, Tappouni HL, Patterson KB, et al. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr. 2008;47:329–333. [PMC free article] [PubMed]
29. Dobard C, Parikh U, Sharma S, et al. Complete protection against repeated vaginal simian HIV exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine [paper #46]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Quebec, Canada.
30. Garcia-Lerma G, Cong ME, Zheng Q, et al. Efficacy of intermittent prophylaxis with tenofovir and emtricitabine against rectal SHIV transmission in macaques and relationship to systemic and mucosal drug levels [paper #83]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; San Francisco, CA.
31. Garcia-Lerma G, Cong ME, Mitchell J, et al. Prevention of rectal simian HIV transmission in macaques by intermittent pre-exposure prophylaxis with oral truvada [paper #47]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Quebec, Canada.
32. Van Rompay KK, Matthews TB, Higgins J, et al. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol. 2002;76:6083–6092. [PMC free article] [PubMed] 33. Eron J, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS. 1998;12:F181–F191. [PubMed] 34. Taylor S, Pereira AS. Antiretroviral drug concentrations in semen of HIV-1 infected men. Sex Transm Infect. 2001;77:4–11. [PMC free article] [PubMed] 35. Ghosn J, Chaix ML, Peytavin G, et al. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men. AIDS. 2004;18:1958–1961. [PubMed] 36. Pereira A, Kashuba AD, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis. 1999;180:2039–2043. [PubMed]
37. Veazey R, Ketas T, Dufour J, et al. Protection of rhesus macaques from vaginal infection by maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor [paper #84LB]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; San Francisco, CA.
40. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PloS Clinical Trials. 2007;2:e27. PMCID: PMC1876601. [PMC free article] [PubMed]
41. Peterson L, Taylor D, Clarke EE, et al. Findings from a double-blind, randomized, placebo-controlled trial of tenofovir disoproxil fumarate (TDF) for prevention of HIV infection in women [abstract THLB0104]. Presented at: XVI International AIDS Conference; August 13–18, 2006; Toronto, Ontario, Canada.
42. Baeten J, Ndase P, Mugo N, et al. the Partners PrEP Study Team. Demographic, behavioral, and clinical characteristics of HIV-1 serodiscordant couples enrolled into an efficacy trial of pre-exposure prophylaxis [paper #959]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; San Francisco, CA.
43. HIV prevention trials require sophisticated community preparation. Controversial PrEP trials serve as cautionary tale. 2009;24:67–69. [PubMed]
44. Abdool Karim S, Coletti A, Richardson B, et al. Safety and effectiveness of vaginal microbicides Buffer Gel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 Trial [paper #48LB]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8–11, 2009; Montreal, Quebec, Canada.
45. Barditch-Crovo P, Deeks SG, Collier A, et al. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2001;45:2733–2739. [PMC free article] [PubMed] 46. Van Rompay KK, Johnson JA, Blackwood EJ, et al. Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. Retrovirology. 2007;6:25. [PMC free article] [PubMed]
47. Smith D. Antiretroviral resistance is not an important risk of the oral tenofovir prophylaxis trial in Botswana: a simple mathematical modelling approach. Presented at: XVI International AIDS Conference; August 13–18, 2006; Toronto, Ontario, Canada.
48. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). Presented at: XVIII International AIDS Conference; July 18–23, 2010; Vienna, Austria.
49. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. the CAPRISA 004 Trial Group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women [published online ahead of print July 19, 2010] Science. doi: 10.1126/science.1193748. [PMC free article] [PubMed] 51. Paltiel A, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis. 2009;48:806–815. [PMC free article] [PubMed] 52. Abbas U, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLos ONE. 2007;2(9):e875. doi:10.1371/journal.pone.0000875. [PMC free article] [PubMed]
53. Mansergh G, Colfax G, McKirnan D, et al. the Project MIX Study Group. Use and sharing of antiretroviral medications for pre- and post-exposure prophylaxis to prevent sexual transmission of HIV among high-risk, substance-using men who have sex with men in 4 US cities [paper #957]. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16–19, 2010; San Francisco, CA.
54. Kellerman SE, Hutchinson AB, Begley EB, et al. Knowledge and use of HIV pre-exposure prophylaxis among attendees of minority gay pride events, 2004. J Acquir Immune Defic Syndr. 2006;43:376–377. [PubMed] 55. Mimiaga MJ, Case P, Johnson CV, et al. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77–83. [PMC free article] [PubMed] 56. Liu AY, Kittredge PV, Vittinghoff E, et al. Limited knowledge and use of HIV post- and pre-exposure prophylaxis among gay and bisexual men. J Acquir Immune Defic Syndr. 2008;47:241–247. [PubMed] 57. Underhill K, Operario D, Skeer M, et al. Packaging PrEP to prevent HIV: an integrated framework to plan for pre-exposure prophylaxis implementation in clinical practice [published online ahead of print August 13, 2010] J Acquir Immune Defic Syndr. doi: 10.1097/QAI.0b013e3181e8efe4. [PMC free article] [PubMed] 58. Burns D, Dieffenbach CW, Vermund SH. Rethinking HIV-1 prevention of HIV type 1 infection published online ahead of print August 13, 2010] Clin Infect Dis. 2010;51 doi: 10.1086/655889. [PMC free article] [PubMed]